Topotecan and the treatment of recurrent ovarian cancer

is there a role for granulocyte colony-stimulating factor?

L. Saltz, John Edward Janik

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Topotecan (Hycamtin; SmithKline Beecham Pharmaceuticals, Philadelphia, PA) a new chemotherapeutic agent for the treatment of patients with advanced carcinoma of the ovary after failure of initial or subsequent therapy, is a specific, potent inhibitor of the enzyme topoisomerase I. Myelosuppression is the dose-limiting toxicity of topotecan, and can interfere with the administration of the recommended dose/schedule of the drug by delaying the next cycle of chemotherapy or by requiring a reduction in the dose. The results from clinical studies suggest that routine granulocyte colony-stimulating factor therapy is not needed when topotecan is administered at the recommended dose of 1.5 mg/m2/d for 5 days. However, patients should be carefully monitored, as some may benefit from hematopoietic growth factor support on subsequent cycles.

Original languageEnglish (US)
JournalSeminars in Oncology
Volume24
Issue number1 Suppl 5
StatePublished - Jan 1 1997

Fingerprint

Topotecan
Granulocyte Colony-Stimulating Factor
Ovarian Neoplasms
Topoisomerase I Inhibitors
Proxy
Therapeutics
Pharmaceutical Preparations
Ovary
Intercellular Signaling Peptides and Proteins
Appointments and Schedules
Carcinoma
Drug Therapy

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Topotecan and the treatment of recurrent ovarian cancer : is there a role for granulocyte colony-stimulating factor? / Saltz, L.; Janik, John Edward.

In: Seminars in Oncology, Vol. 24, No. 1 Suppl 5, 01.01.1997.

Research output: Contribution to journalReview article

@article{33bfe2035bf4444382deab089ee87ab2,
title = "Topotecan and the treatment of recurrent ovarian cancer: is there a role for granulocyte colony-stimulating factor?",
abstract = "Topotecan (Hycamtin; SmithKline Beecham Pharmaceuticals, Philadelphia, PA) a new chemotherapeutic agent for the treatment of patients with advanced carcinoma of the ovary after failure of initial or subsequent therapy, is a specific, potent inhibitor of the enzyme topoisomerase I. Myelosuppression is the dose-limiting toxicity of topotecan, and can interfere with the administration of the recommended dose/schedule of the drug by delaying the next cycle of chemotherapy or by requiring a reduction in the dose. The results from clinical studies suggest that routine granulocyte colony-stimulating factor therapy is not needed when topotecan is administered at the recommended dose of 1.5 mg/m2/d for 5 days. However, patients should be carefully monitored, as some may benefit from hematopoietic growth factor support on subsequent cycles.",
author = "L. Saltz and Janik, {John Edward}",
year = "1997",
month = "1",
day = "1",
language = "English (US)",
volume = "24",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "1 Suppl 5",

}

TY - JOUR

T1 - Topotecan and the treatment of recurrent ovarian cancer

T2 - is there a role for granulocyte colony-stimulating factor?

AU - Saltz, L.

AU - Janik, John Edward

PY - 1997/1/1

Y1 - 1997/1/1

N2 - Topotecan (Hycamtin; SmithKline Beecham Pharmaceuticals, Philadelphia, PA) a new chemotherapeutic agent for the treatment of patients with advanced carcinoma of the ovary after failure of initial or subsequent therapy, is a specific, potent inhibitor of the enzyme topoisomerase I. Myelosuppression is the dose-limiting toxicity of topotecan, and can interfere with the administration of the recommended dose/schedule of the drug by delaying the next cycle of chemotherapy or by requiring a reduction in the dose. The results from clinical studies suggest that routine granulocyte colony-stimulating factor therapy is not needed when topotecan is administered at the recommended dose of 1.5 mg/m2/d for 5 days. However, patients should be carefully monitored, as some may benefit from hematopoietic growth factor support on subsequent cycles.

AB - Topotecan (Hycamtin; SmithKline Beecham Pharmaceuticals, Philadelphia, PA) a new chemotherapeutic agent for the treatment of patients with advanced carcinoma of the ovary after failure of initial or subsequent therapy, is a specific, potent inhibitor of the enzyme topoisomerase I. Myelosuppression is the dose-limiting toxicity of topotecan, and can interfere with the administration of the recommended dose/schedule of the drug by delaying the next cycle of chemotherapy or by requiring a reduction in the dose. The results from clinical studies suggest that routine granulocyte colony-stimulating factor therapy is not needed when topotecan is administered at the recommended dose of 1.5 mg/m2/d for 5 days. However, patients should be carefully monitored, as some may benefit from hematopoietic growth factor support on subsequent cycles.

UR - http://www.scopus.com/inward/record.url?scp=0031064505&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031064505&partnerID=8YFLogxK

M3 - Review article

VL - 24

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 1 Suppl 5

ER -